BiotechTube

E5555 50 mg + E5555 100 mg + E5555 200 mg + Placebo

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Coronary Artery Disease

Conditions

Coronary Artery Disease

Trial Timeline

Oct 1, 2007 → —

NCT ID
NCT00540670

About E5555 50 mg + E5555 100 mg + E5555 200 mg + Placebo

E5555 50 mg + E5555 100 mg + E5555 200 mg + Placebo is a phase 2 stage product being developed by Eisai for Coronary Artery Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT00540670. Target conditions include Coronary Artery Disease.

What happened to similar drugs?

20 of 20 similar drugs in Coronary Artery Disease were approved

Approved (20) Terminated (2) Active (0)
✅EvolocumabHeartFlowApproved
✅Clopidogrel treatment groupYuhanApproved
✅high-dose rosuvastatin + low-dose rosuvastatin plus ezetimibeYuhanApproved
✅statins, ezetimibe + Combination therapyYuhanApproved
✅Modification of Prasugrel based on a biological assay + prasugrel / clopidogrelDaiichi SankyoApproved
✅PrasugrelDaiichi SankyoApproved
✅Prasugrel + ClopidogrelDaiichi SankyoApproved

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00540670Phase 2Completed

Competing Products

20 competing products in Coronary Artery Disease

See all competitors
ProductCompanyStageHype Score
Rosuvastatin 40mg + PlaceboHeartFlowPre-clinical
27
EvolocumabHeartFlowApproved
29
High intensity lipid loweringHeartFlowPre-clinical
20
ExenatideEli LillyPhase 3
40
Clopidogrel treatment groupYuhanApproved
50
YH14659 + clopidogrel & aspirinYuhanPhase 1
29
high-dose rosuvastatin + low-dose rosuvastatin plus ezetimibeYuhanApproved
43
Sarpogrelate + Aspirin + Clopidogrel + Placebo (for Sarpogrelate)YuhanPhase 3
40
statins, ezetimibe + Combination therapyYuhanApproved
50
YH14659 + clopidogrel & aspirinYuhanPhase 1
29
Modification of Prasugrel based on a biological assay + prasugrel / clopidogrelDaiichi SankyoApproved
43
clopidogrel + prasugrelDaiichi SankyoPhase 1
21
PrasugrelDaiichi SankyoApproved
43
ADP receptor inhibitorsDaiichi SankyoPre-clinical
26
Pactimibe, CS-505Daiichi SankyoPhase 2
35
Prasugrel + ClopidogrelDaiichi SankyoPhase 2
35
prasugrel + clopidogrelDaiichi SankyoPhase 1
29
Prasugrel + ClopidogrelDaiichi SankyoApproved
43
Triple oral lipid lowering treatmentDaiichi SankyoPhase 3
47
Placebo + PrasugrelDaiichi SankyoPhase 3
40